Skip to content

Trial · Interventional

Status unknownNot applicableRegistry data

Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

NCTNCT02490176 (opens ClinicalTrials.gov in a new tab)Other idS2015-095-01
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Status unknown
Phase
Not applicable
Enrollment
50 participants (estimated)
Sponsor
Chinese PLA General Hospital · Other
Design
Randomized · Double masking
Countries
1 country

China

Start
Jul 2015
Primary completion
Jul 2016 (estimated)
Completion
Jul 2016 (estimated)
First posted
3 Jul 2015 (estimated)
Last update posted
29 Feb 2016 (estimated)
Conditions
Heart Failure

Timeline

1 trial

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201520162017
  1. N/A

    Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters

    NCT02490176

    Jul 2015 to est. Jul 2016

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction. The investigators planned to evaluate the effects of liraglutide on haemodynamic parameters in patients with heart failure.

Interventions

  • liraglutideDrug
  • placeboDrug

Arms2

  • Experimental

    GLP-1 group

    drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.

  • Placebo comparator

    Control group

    drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology

    Time frame · 7 days after treatment

    Registry description

    The primary efficacy endpoint was the effect of liraglutide on cardiac output (CO) at 7 days compared with placebo.

Secondary outcomes(1)

  1. a change in left ventricular contractile index measured by PiCCO technology

    Time frame · 7 days after treatment

    Registry description

    The change in left ventricular contractile index was measured at 7 days after treatment.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies3

Studies that cite this trial.

Studies with results

2 studies on this page

Indexing hint: Randomized controlled trial · 2012

8 results

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.

Lønborg et al. 2012European heart journalcited by 421

PMID 21920963DOI 10.1093/eurheartj/ehr309PUB-21920963

Rights unknown8 results
Source linkSee results (8)

Indexing hint: Animal study · 2009

12 results

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

Timmers et al. 2009Journal of the American College of Cardiologycited by 361

PMID 19195607DOI 10.1016/j.jacc.2008.10.033PUB-19195607

Full text at the publisher12 results
Publisher pageSee results (12)

More studies

1 study on this page

PubMed tag: none · 2009

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Noyan-Ashraf et al. 2009Diabetescited by 463

PMID 19151200PMC2661586DOI 10.2337/db08-1193PUB-19151200

Free to read · publisher termsCC BY-NC-ND
Read at source

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 80 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: Patients with HF were eligible for the study. Diagnosis of HF was based on an impaired ejection fraction (\<50%). Exclusion Criteria: Patients were also excluded for the following reasons: unconscious at presentation; valvular heart disease, cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; or renal insufficiency.

PepBank is a research reference. Talk to a doctor before you use any peptide.